Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

Nonurinary sodium excretion in afebrile cirrhotic patients without diarrhea is approximately 10 mmol/day. [13] Patients with ascites on no diuretics commonly have renal sodium excretion of < 20 ...

A thrombopoietin agonist raises platelet counts in HCV-positive patients who are undergoing antiviral therapy. Cirrhotic patients who are infected with hepatitis C virus (HCV) often experience ...

Beyond the rise in Nrf2, C. molmol resin treatment also reduced protein tumour necrosis factor-alpha (TNF-α), which is known to be high in the serum of cirrhotic patients, a condition in which ...

MASH's economic burden is substantial, particularly for patients with MASH and multiple comorbidities, even in the absence of ...

A cross-sectional study of cardiovascular devices subject to Class I recalls from 2013 through 2022, found that most recalled devices did not undergo clinical testing before authorization and were not ...

The gut microbiome has been well-established in its role of regulating the onset of many gastrointestinal disorders. Recent ...

A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...

In California, the animal you run over cannot be carted off to your freezer. It must stay by the side of the road. California ...

Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Akero Therapeutics (AKRO – Research Report). The associated price ...

The gut microbiota and its functional metabolites play crucial roles in the development of intestinal fibrosis in patients ...